ReviewCurrent oncology reports2019
Acute Myeloid Leukemia: Update on Upfront Therapy in Elderly Patients.
Review in Current oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Survival in Elderly Patients Diagnosed With Acute Myeloid Leukemia: A Hospital-Based Study.Journal of hematology · 2023Article
- Hematopoietic stem cell microtransplantation in patients aged over 70 with acute myeloid leukemia: a multicenter study.American journal of cancer research · 2023Article
- Correlation Analysis and Prognostic Impacts of Biological Characteristics in Elderly Patients with Acute Myeloid Leukemia.Clinical interventions in aging · 2022Article
- Non-Ablative Chemotherapy Followed by HLA-Mismatched Allogeneic CD3Frontiers in oncology · 2021Article
- Article
- Article
- Improving awareness of several combination therapies for acute myeloid leukemia among oncology and hematology team members in Colorado, USA.Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAcute myeloid leukemia (AML) disproportionately impacts elderly patients. Treating elderly patients with AML has been a challenge due to the increased prevalence of medical comorbidities and decreased performance status in this population, as well as the different biology of AML in elderly patients. RECENT
findingsThe care of elderly patients with AML has advanced significantly over the past few years. Our greater understanding of the biology of AML in elderly patients has led to the development of novel, lower-intensity treatment options. We present here a review of the most recent literature regarding therapeutic options available to older patients, as well as tools to help identify the right treatment for the right patient. As targeted and lower-intensity treatment options become available, developing an approach to "right size" therapy for individual elderly patients is paramount.
Indexed as
Identifiers
31250135What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.